Triplebar Bio Inc

Triplebar Bio Inc. is a biotechnology company that integrates hardware, software, and biology to accelerate the discovery and production of therapeutics and sustainable food products. The company’s core technology is a proprietary microfluidics platform that miniaturizes biological testing into picoliter-volume microreactors. This system allows for the screening of tens to hundreds of millions of individual cells daily to analyze their phenotype and genotype. By combining this high-throughput data generation with generative AI genome language models, Triplebar enables Genomic Design Automation (GDA), which significantly reduces the time and cost required for strain and cell line engineering compared to traditional methods.

This technology provides vital solutions for the healthcare and food industries by streamlining the development of high-performance biologics and alternative proteins. The platform, which includes specialized tools like eiCHO for biologics production and eiMICRO for cell line engineering, helps partners navigate the complexities of biological systems more efficiently. By identifying optimal cellular behaviors at hyperspeed, Triplebar enables companies to bypass lengthy, manual lab processes, supporting the creation of sustainable and cost-effective solutions for global supply and health challenges. The company, headquartered in Emeryville, California, has attracted significant investment to scale its efforts in re-engineering production systems across the life sciences.